Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure (PREVENTA)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00925470
First received: June 19, 2009
Last updated: December 17, 2009
Last verified: December 2009
  Purpose

Evaluation of target organs impairment on patients suffering from high blood pressure without known cardio vascular or renal disease, stratified on blood pressure control.


Condition
Blood Pressure

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure Without Known Cardio Vascular or Renal Disease, Stratified on Blood Pressure Control.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate the frequency of evaluation of target organs preclinical impairment on patients without known cardiovascular or renal disease, taking into consideration the blood pressure level (controlled HBP or not) [ Time Frame: Once ] [ Designated as safety issue: No ]

Estimated Enrollment: 1200
Study Start Date: June 2009
Study Completion Date: December 2009

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

First 2 consecutive adults with hypertension, without known cardio vascular or renal disease,seen by Cardiologists

Criteria

Inclusion Criteria:

  • Adults with hypertension (treated or not), without known cardiovascular or renal disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00925470

  Show 375 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne, Medical Director AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00925470     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2009/1
Study First Received: June 19, 2009
Last Updated: December 17, 2009
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Target organs impairment
High blood pressure
Evaluation of target organs impairment on patients suffering from high blood pressure without known cardiovascular or renal disease

Additional relevant MeSH terms:
Hypertension
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 27, 2014